Human Genome Sciences
Global biopharma focused on discovery, development and manufacture of specialty medicines and vaccines. R&D emphasises immune-system biology, human genetics and platform technologies supported by AI/ML and large-scale data platforms. Operates a distributed network of regional R&D sites and global manufacturing and supply chain infrastructure; publishes policies and reports on safety, environmental and governance standards. Public site descriptions indicate multiple specialised R&D hubs (vaccine discovery, AI/ML research, medical and regulatory affairs, technology R&D, clinical supply chain and large smart-lab campuses) across the US and other regions.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Methods and compositions for use in treatment of patients with autoantibody positive disease
US-9168286-B2
View Details
Methods and compositions for use in treatment of patients with autoantibody positive disease
US-9168286-B2
View DetailsProducts
Specialty medicines
Prescription medicines for specialist healthcare settings across areas such as HIV, respiratory, immune-mediated conditions and oncology.
Vaccines
Portfolio of vaccines for childhood and adult immunisation, manufactured under standardised quality systems across multiple sites.
General medicines
Medicines for primary care settings, including treatments for respiratory conditions and commonly prescribed antibiotics.
Specialty medicines
Prescription medicines for specialist healthcare settings across areas such as HIV, respiratory, immune-mediated conditions and oncology.
Vaccines
Portfolio of vaccines for childhood and adult immunisation, manufactured under standardised quality systems across multiple sites.
General medicines
Medicines for primary care settings, including treatments for respiratory conditions and commonly prescribed antibiotics.
Services
Partnerships with academic, public and commercial organisations for access to datasets, co-development and translational research.
Data-driven design of trials, patient identification and recruitment optimisation, and management of representative and first-in-human studies.
Large-scale manufacturing network and quality systems for vaccines and medicines, including process simulation, automation and supply-chain distribution.
Development and operation of data infrastructure and analytics platforms to support R&D, manufacturing optimisation and AI/ML workflows.
Public registry and processes to publish clinical-study metadata, results and supporting information to support transparency and external research use.
Partnerships with academic, public and commercial organisations for access to datasets, co-development and translational research.
Data-driven design of trials, patient identification and recruitment optimisation, and management of representative and first-in-human studies.
Large-scale manufacturing network and quality systems for vaccines and medicines, including process simulation, automation and supply-chain distribution.
Development and operation of data infrastructure and analytics platforms to support R&D, manufacturing optimisation and AI/ML workflows.
Public registry and processes to publish clinical-study metadata, results and supporting information to support transparency and external research use.
Expertise Areas
- Clinical trial management and optimisation
- Platform therapeutics (oligonucleotides, mRNA, antibodies, small molecules)
- Vaccine research and large-scale vaccine manufacturing
- Human genetics and population-scale target discovery
Key Technologies
- Artificial intelligence / machine learning
- Cloud-scale data platforms and enterprise analytics
- Human genetics and functional genomics
- Modular antigen-display vaccine platforms
News & Updates
Reported R&D investment of £6.4bn in 2024.
Approximately 71 medicines and vaccines in development (2024).
Operating a global network of 37 medicines and vaccines manufacturing sites.
Delivered 2.1 billion packs of medicines and doses of vaccines in 2024.
Reported delivery of more than 1 million vaccine doses per day.
Reported R&D investment of £6.4bn in 2024.
Approximately 71 medicines and vaccines in development (2024).
Operating a global network of 37 medicines and vaccines manufacturing sites.
Delivered 2.1 billion packs of medicines and doses of vaccines in 2024.
Reported delivery of more than 1 million vaccine doses per day.